CompletedNCT01674361
A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With OCD (OCD)
Medication studyAges 18–65Canada + United States
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Oceanside and 33 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 31, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 99
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01674361
- Official title
Show the full official title
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder
Recruitment & locations
CompletedOceanside, United States · Stanford, United States · New Haven, United States
29 more locations
- Leesburg, United States
- Orange City, United States
- St. Petersburg, United States
- Tampa, United States
- Decatur, United States
- Smyrna, United States
- Chicago, United States
- New Orleans, United States
- Boston, United States
- Minneapolis, United States
- Flowood, United States
- St Louis, United States
- New York, United States
- Rochester, United States
- Middleburg Heights, United States
- Oklahoma City, United States
- Norristown, United States
- Providence, United States
- Memphis, United States
- Austin, United States
- Kirkland, United States
- Middleton, United States
- Edmonton, Canada
- Kelowna, Canada
- Halifax, Canada
- Kentville, Canada
- Hamilton, Canada
- Mississauga, Canada
- Toronto, Canada
Questions about this study
Who is behind this study?
The study sponsor is Hoffmann-La Roche.
Did this study involve medication?
Yes. The study involved medication, including Bitopertin, Placebo and SSRI.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me